# ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

Source: https://onco.cc/trials/nct05355298/  
OnCo record `nct05355298` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AMP945 ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.

## Summary

ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05355298 by Amplia Therapeutics Limited, with 62 participants enrolled, started 2022-05-31 and due to reach its primary completion in 2027-02-01. Interventions recorded: AMP945 ascending doses and AMP945 RP2D.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05355298
- Phase: 1/2
- Setting: A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients
- Sponsor: Amplia Therapeutics Limited
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT05355298: https://clinicaltrials.gov/study/NCT05355298

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct05355298.json